Skip to main content

Table 2 Overall survival estimates in de novo stage IV patients on univariate and multivariate models

From: Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer

  Univariate Multivariate
Variable HR 95%CI P HR 95% CI P
Luminal-like 1    1   
HER2–enriched 2.0 1.4-2.8 < 0.0001 2.2 1.5-3.1 < 0.0001
Triple negative 4.2 2.8-6.2 < 0.0001 4.3 2.9-6.5 < 0.0001
cT1-3 vs. cT4 0.7 0.5-0.9 0.011    
NG 1–2 vs. NG 3 0.9 0.5-1.4 0.5386    
LVI
  focal vs. no 0.6 0.3-1.4 0.2649    
  Prominent vs. no 0.5 0.3-1.0 0.0616    
Lymph node involvement 1.1 0.8-1.5 0.6471    
CEA elevated vs. normal 1.1 0.8-1.5 0.3969    
CA 153 elevated vs. normal 1.1 0.8-1.4 0.6379    
Metastasis
  Liver, yes vs. no 2.3 1.7-3.2 < 0.0001 1.9 1.4-2.5 0.0001
  Lung, yes vs. no 1.7 1.3-2.2 0.0004 1.4 1.1-1.9 0.0153
  Brain, yes vs. no 1.5 1.1-2.3 0.0256 1.3 0.9-1.9 0.1728
  Bone, yes vs. no 1.3 0.9-1.8 0.1016 1.8 1.3-2.5 0.0007
*Local treatment, yes vs. no 0.5 0.4-0.6 < 0.0001 0.6 0.4-0.8 0.0008
  1. Note: *Local treatment: surgery, radiotherapy, or both.